Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia
University Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK. Clinical Pharmacology & Therapeutics
(Impact Factor: 7.9).
03/2008; 83(2):258-64. DOI: 10.1038/sj.clpt.6100268
Some chronic myeloid leukemia (CML) patients do not respond to imatinib, whereas others lose an initial response. To identify potential imatinib failures, we investigated the expression of imatinib uptake transporter (human organic cation transporter 1; hOCT1) and efflux transporters (ATP-binding cassette transporters ABCB1, ABCG2, and ABCC1) using real-time quantitative reverse transcription-polymerase chain reaction in 70 CML patients. Patients with high pretreatment hOCT1 expression had superior complete cytogenetic response (CCR) rates (P=0.008), progression-free and overall survival (P=0.01 and 0.004). Pretreatment ABCB1, ABCG2, and ABCC1 levels did not correlate with treatment outcome. Regression analysis demonstrated that pretreatment hOCT1 expression was the most powerful predictor of CCR achievement at 6 months (P=0.002). Imatinib uptake into a CML cell line with high hOCT1 expression was greater than into those with modest or low expression (P=0.002). The expression of hOCT1, but not efflux transporters, is important in determining the clinical response to imatinib.
Figures in this publication
Available from: Alex Sparreboom
- "SLC22A1 has been suggested to largely determine the IUR of imatinib, and its expression/activity are thought to predict the long-term outcome of chronic-phase CML cells (Thomas et al., 2004; Crossman et al., 2005; White et al., 2006, 2007, 2010; Wang et al., 2008; White and Hughes, 2012). SLC22A1 transporter activity is commonly derived from the IUR of imatinib with and without " specific " SLC22A1 inhibitors such as prazosin or amantadine. "
[Show abstract] [Hide abstract]
ABSTRACT: The intracellular uptake and retention (IUR) of imatinib is reported to be controlled by the influx transporter SLC22A1 (OCT1). We recently hypothesized that alternative uptake and/or retention mechanisms exist that determine intracellular imatinib levels. Here we systematically investigate the nature of these mechanisms. Imatinib uptake in cells was quantitatively determined by LC-MS-MS. Fluorescent microscopy was used to establish subcellular localization of imatinib. Immunoblotting, cell cycle analyses and apoptosis assays were done to evaluate functional consequences of imatinib sequestration. Uptake experiments revealed high intracellular imatinib concentrations in HEK293, the leukemic cell lines K562, SD-1, and a gastrointestinal stromal tumor cell line GIST-T1. We demonstrated that imatinib IUR is time, dose, temperature and energy dependent and provide evidence that SLC22A1 and other potential imatinib transporters do not substantially contribute to the IUR of imatinib. Prazosin, amantadine, NH4Cl and the V-ATPase inhibitor bafilomycin A1 significantly decreased the IUR of imatinib and likely interfere with lysosomal retention and accumulation of imatinib. Co-staining experiments with Lysotracker Red confirmed lysosomal sequestration of imatinib. Inhibition of the lysosomal sequestration had no effect on the inhibition of c-Kit signaling and imatinib mediated cell cycle arrest but significantly increased apoptosis in imatinib sensitive GIST-T1 cells. We conclude that intracellular imatinib levels are primarily determined by lysosomal sequestration and do not depend on SLC22A1 expression.
The American Society for Pharmacology and Experimental Therapeutics.
Molecular pharmacology 06/2015; 88(3). DOI:10.1124/mol.114.097451 · 4.13 Impact Factor
Available from: Necmiye Kaci
- "Decreasing hOCT1 levels cause a low intracellular concentration of imatinib in the cytoplasm, and therefore the therapeutic activity of the drug is weakened in the cell (Wang et al., 2008). As a second-line treatment agent, nilotinib is administered to imatinib-resistant patients with CML. "
[Show abstract] [Hide abstract]
ABSTRACT: Chronic myeloid leukemia (CML) is characterized by the accumulation of Philadelphia chromosome-positive (Ph+) myeloid cells. Ph+ cells occur via a reciprocal translocation between the long arms of chromosomes 9 and 22 resulting in constitutively active Bcr-abl fusion protein. Tyrosine kinase inhibitors (TKIs) are used against the kinase activity of Bcr-abl fusion protein for the effective treatment of CML. However, the development of drug resistance, directed by different genetic mechanisms, is the major problem of clinical applications of TKIs. These mechanisms include mutations in the TKI binding site of Bcr-abl, overexpression of Bcr-abl, overexpression of ATP binding cassette transporters, aberrant ceramide metabolism, inhibition of apoptosis, and changes in expression levels of microRNAs. Recently, many studies have focused on understanding the molecular mechanisms of drug resistance in cancer while targeting therapies providing reversal of resistance. Cancer stem cells also have roles in tumor initiation, maintenance, progression,
metastasis, and drug resistance. Uncovering the mechanisms of drug resistance can provide more efficient treatment of cancer since these findings may provide novel targets for a complete cure. In this review, we discuss recent findings on the mechanisms of multidrug resistance and its reversal in CML.
Turkish Journal of Biology 11/2014; DOI:10.3906/biy-1405-21 · 1.34 Impact Factor
Available from: Sara Eyal
- "The most established cause of secondary resistance is the occurrence of mutations in the catalytic domain of the kinase, which restrict the binding of currently available TKIs (Levitzki and Mishani, 2006). In addition, primary or secondary resistance may result from insufficient intracellular drug concentrations , due to poor uptake (Wang et al., 2008; Engler et al., 2011; Mandery et al., 2012) or active efflux transport (Ozvegy- Laczka et al., 2005; Eadie et al., 2014). Two prominent transporters involved in drug efflux from cells are P-gp (multidrug resistance Abbreviations: ABC, adenosine triphosphate binding cassette; BCRP, breast cancer resistance protein; EGFR, epidermal growth factor receptor; EGFRI, epidermal growth factor receptor kinase inhibitor; FTC, fumitremorgin C; PET, positron emission tomography; P-gp, P-glycoprotein; TKI, tyrosine kinase inhibitor. "
[Show abstract] [Hide abstract]
ABSTRACT: The objective of this study was to investigate in vitro the interactions between novel epidermal growth factor receptor kinase inhibitors (EGFRIs) developed for positron emission tomography (PET) imaging and the major eﬄux transporter breast cancer resistance protein (BCRP/ABCG2). Seven compounds were evaluated, using the ATPase activity assays and Madin-Darbey canine kidney (MDCK) cells overexpressing BCRP. Five of the tested compounds activated BCRP ATPase to various extent. Overexpression of BCRP conferred resistance to ML04, ML06, methoxy-Br-ML03, and PEG6-ML05 (IC50 values for inhibition of control cell proliferation 2.1 ± 0.6, 2.2 ± 0.7, 1.8 ± 1.2, and 2.8 ± 3.1 μM, respectively, compared to >50 μM in MDCK-BCRP cells). At submicromolar concentrations, none of the EGFRIs significantly inhibited BCRP. Immunoblotting studies indicated that BCRP expression is evident in cell lines utilized for in vivo tumor grafting in small animal PET imaging studies. Thus, the intensity of EGFRIs radioactivity signals previously observed in tumor xenografts reflects an interplay between transporter-mediated distribution of the probe into tumor cells and target binding. Concomitant use of eﬄux transporter inhibitors may help distinguish between the contribution of eﬄux transport and EGFR binding to the tissue signal.
Frontiers in Pharmacology 11/2014; 5:257. DOI:10.3389/fphar.2014.00257 · 3.80 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.